Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Lamotrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 9/20 | 0.97 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.97 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.97 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.97 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.97 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | MAOA | P21397 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.97 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamotrigine SCHEMBL29360953 | 0.98 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL29801510 | 0.98 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL35439 | 0.98 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL722975 | 0.98 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL17372723 | 0.97 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL4142403 | 0.97 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976546 | 0.97 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3167376 | 0.97 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976541 | 0.94 | SCN9A (0.91) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL6138267 | 0.90 | SCN9A (0.83) | SCN9ACYP2D6MAOAMAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190249147-A1 | BIOLOGICALLY RELEVANT IN VITRO SCREENING OF HUMAN NEURONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-08-15 | — | — | US | disclosed |
| WO-2017223052-A1 | BIOLOGICALLY RELEVANT IN VITRO SCREENING OF HUMAN NEURONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-2292217-A2 | Modified release lamotrigine tablets | Ranbaxy Laboratories Limited (IN) | 2011-03-09 | — | — | EP | disclosed |
| US-20110052686-A1 | MODIFIED RELEASE LAMOTRIGINE TABLETS | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052686-A1 | MODIFIED RELEASE LAMOTRIGINE TABLETS | GABRE, GRIK5, KCNQ5 | SCN9A 786/4885SCN4A 852/4885SCN5A 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.